Abstract:Accumulating evidence indicates that oncogenic viral protein plays a crucial role in activating aerobic glycolysis during tumorigenesis, but the underlying mechanisms are largely undefined. Epstein-Barr virus ( EBV)-encoded latent membrane protein 1 ( LMP1) is a transmembrane protein with potent cell signaling properties and has tumorigenic transformation property. Activation of NF-kappa B is a major signaling pathway mediating many downstream transformation properties of LMP1. Here we report that activation of mTORC1 by LMP1 is a key modulator for activation of NF-kappa B signaling to mediate aerobic glycolysis. NF-kappa B activation is involved in the LMP1-induced upregulation of glucose transporter 1 ( Glut-1) transcription and growth of nasopharyngeal carcinoma ( NPC) cells. Blocking the activity of mTORC1 signaling effectively suppressed LMP1-induced NF-kappa B activation and Glut-1 transcription. Interfering NF-kappa B signaling had no effect on mTORC1 activity but effectively altered Glut-1 transcription. Luciferase promoter assay of Glut-1 also confirmed that the Glut-1 gene is a direct target gene of NF-kappa B signaling. Furthermore, we demonstrated that C-terminal activating region 2 ( CTAR2) of LMP1 is the key domain involved in mTORC1 activation, mainly through IKK beta-mediated phosphorylation of TSC2 at Ser(939). Depletion of Glut-1 effectively led to suppression of aerobic glycolysis, inhibition of cell proliferation, colony formation, and attenuation of tumorigenic growth property of LMP1- expressing nasopharyngeal epithelial ( NPE) cells. These findings suggest that targeting the signaling axis of mTORC1/NF-kappa B/ Glut-1 represents a novel therapeutic target against NPC. IMPORTANCE Aerobic glycolysis is one of the hallmarks of cancer, including NPC. Recent studies suggest a role for LMP1 in mediating aerobic glycolysis. LMP1 expression is common in NPC. The delineation of essential signaling pathways induced by LMP1 in aerobic glycolysis contributes to the understanding of NPC pathogenesis. This study provides evidence that LMP1 upregulates Glut-1 transcription to control aerobic glycolysis and tumorigenic growth of NPC cells through mTORC1/NF-kappa B signaling. Our results reveal novel therapeutic targets against the mTORC1/NF-kappa B/Glut-1 signaling axis in the treatment of EBV-infected NPC.

EBV-miR-BART1-5P Activates AMPK/mTOR/HIF1 Pathway Via a PTEN Independent Manner to Promote Glycolysis and Angiogenesis in Nasopharyngeal Carcinoma

Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy

Epstein–Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma

Targeting Epstein|[ndash]|Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy

Correction: EBV-miR-BART1-5P Activates AMPK/mTOR/HIF1 Pathway Via a PTEN Independent Manner to Promote Glycolysis and Angiogenesis in Nasopharyngeal Carcinoma

Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell metastasis and invasion by targeting long non-coding RNA LOC553103

Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Upregulates Glucose Transporter 1 Transcription via the mTORC1/NF-κB Signaling Pathways

Metabolic reprogramming in the pathogenesis and progression of nasopharyngeal carcinoma: molecular mechanisms and therapeutic implications

EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways

EBV encoded miRNA BART8-3p promotes radioresistance in nasopharyngeal carcinoma by regulating ATM/ATR signaling pathway

Ebv-Mir-Bart10-3p Facilitates Epithelial-Mesenchymal Transition And Promotes Metastasis Of Nasopharyngeal Carcinoma By Targeting Btrc

Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma

Metabolic Reprogramming in Nasopharyngeal Carcinoma: Mechanisms and Therapeutic Opportunities.

Epstein-Barr virus (EBV) encoded microRNA BART8-3p drives radioresistance-associated metastasis in nasopharyngeal carcinoma

EBV‐miR‐BART12 Accelerates Migration and Invasion in EBV‐associated Cancer Cells by Targeting Tubulin Polymerization‐promoting Protein 1

Targeting exosomes enveloped EBV‐miR‐BART1‐5p‐antagomiRs for NPC therapy through both anti‐vasculogenic mimicry and anti‐angiogenesis

Epstein-Barr Virus-Coded Mir-Bart13 Promotes Nasopharyngeal Carcinoma Cell Growth and Metastasis Via Targeting of the NKIRAS2/NF-κB Pathway.

EBV-miR-BART12 accelerates cancer cell migration and invasion through targeting TPPP1 in EBV associated cancer

Exosomal Delivery of AntagomiRs Targeting Viral and Cellular MicroRNAs Synergistically Inhibits Cancer Angiogenesis.

Epstein–Barr virus microRNA miR-BART2-5p accelerates nasopharyngeal carcinoma metastasis by suppressing RNase III endonuclease DICER1

Epstein‐Barr virus‐driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinoma